STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 99 filers reported holding STOKE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.42 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $278,357 | +27.6% | 26,186 | 0.0% | 0.00% | – |
| Q1 2023 | $218,129 | -9.8% | 26,186 | 0.0% | 0.00% | – |
| Q4 2022 | $241,697 | -29.1% | 26,186 | 0.0% | 0.00% | – |
| Q3 2022 | $341,000 | -25.7% | 26,186 | -24.6% | 0.00% | -100.0% |
| Q2 2022 | $459,000 | -37.2% | 34,714 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $731,000 | -12.2% | 34,714 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $833,000 | +12.4% | 34,714 | +19.2% | 0.00% | 0.0% |
| Q3 2021 | $741,000 | -11.2% | 29,114 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $834,000 | -42.0% | 29,114 | -21.3% | 0.00% | -50.0% |
| Q1 2021 | $1,438,000 | -25.9% | 37,014 | +18.1% | 0.00% | 0.0% |
| Q4 2020 | $1,941,000 | +160.2% | 31,341 | +40.7% | 0.00% | +100.0% |
| Q3 2020 | $746,000 | +40.5% | 22,279 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $531,000 | +4.1% | 22,279 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $510,000 | -9.4% | 22,279 | +12.1% | 0.00% | 0.0% |
| Q4 2019 | $563,000 | +31.9% | 19,879 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $427,000 | – | 19,879 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 16,786,713 | $562,187,000 | 75.80% |
| RTW INVESTMENTS, LP | 3,544,248 | $118,697,000 | 2.86% |
| Cormorant Asset Management, LP | 1,537,807 | $51,501,000 | 1.98% |
| Redmile Group, LLC | 2,549,506 | $85,383,000 | 1.57% |
| Birchview Capital, LP | 40,000 | $1,340,000 | 0.45% |
| HighVista Strategies LLC | 17,082 | $572,000 | 0.42% |
| Perceptive Advisors | 671,978 | $22,505,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,490,153 | $49,905,000 | 0.31% |
| Artal Group S.A. | 270,750 | $9,067,000 | 0.22% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 323 | $11,000 | 0.20% |